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Abstract 
Objectives: Dementia is a debilitating condition characterised by global loss of cognitive and 
intellectual functioning, which reduces social and occupational performance. This population 
frequently present with medical co-morbidities such as hypertension, cardiovascular disease and 
diabetes. The CONSORT statement outlines recommended guidance on reporting of participant 
characteristics in clinical trials. It is however unclear how much these are adhered to in trials 
assessing people with dementia. This paper assesses the reporting of medical co-morbidities and 
prescribed medications for people with dementia within randomised controlled trial (RCT) reports.  
Design: A systematic review of the published literature from the databases AMED, CINAHL, 
MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1st January 1997 to 9th January 
2014, to identify RCTs detailing baseline medical co-morbidities and prescribed medications was 
undertaken. Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) 
RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence.  
Results: Nine trials including 1474 people with dementia were identified presenting medical co-
morbidity data. These indicated neurological disorders (prevalence 91%), vascular disorders 
(prevalence 91%), cardiac disorders (prevalence 74%) and ischaemic cerebrovascular disease 
(prevalence 53%) were most frequently seen.  
Conclusions: Published RCTs poorly report medical co-morbidities and medications for people with 
dementia. Future trials should include report of these items to allow interpretation of whether the 
results are generalisable to frailer older older populations. 
PROSPERO Registration: CRD42013006735 
Keywords:  Cognitive impairment; dementia ; co-morbidity; elderly; systematic review 
Key Points: 
 Dementia is a growing health challenge for primary and secondary care providers worldwide. 
 CONSORT statement recommends participant demographic information be provide to ease 
trial generalisability. 
 Currently medical co-morbidities and medicine prescribing is poorly reported in randomised 
controlled trials in dementia. 
 Future research must address this limitation to improve reporting of medical comorbidities 
and prescribed medications.
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Introduction 
Dementia is a debilitating condition characterised by global loss of cognitive and intellectual 
functioning, which gradually interferes with social and occupational performance. It is anticipated that 
the incidence of people with dementia will increase during the next 25 years due to the ageing 
population [1]. Since dementia is most frequently associated with older people, people with dementia 
most commonly present with additional co-existing medical conditions. Such co-morbidities may 
include diabetes, chronic obstructive pulmonary disorder, musculoskeletal disorders and chronic 
cardiac failure [2]. 
No studies have previously attempted to determine what the co-morbidities of this group of people 
are. This is important as it will highlight what the common care needs are, based on a diagnosis of 
dementia and other medical conditions, which this population share. Given documented difficulties in 
people with dementia accessing healthcare resources and communicating medical complaints [3], a 
greater awareness of all the physical and mental health needs of this group of people is important.  
The CONSORT statement was developed to improve the reporting of randomised controlled trials 
(RCTs) published within the literature [4]. Item 15 of the 2010 CONSORT statement emphasises the 
importance of identifying key variables at baseline which may have prognostic strength of the 
variables measured. Therefore the reporting of comorbidities in RCTs, can be considered essential 
practice for people with dementia. Given this importance, the purpose of this paper was to: (1) 
identify the medical co-morbidities have been reported for people with dementia who have been 
recruited into trials; and (2) to assess the frequency of reporting for medical co-morbidities within the 
literature for this population.  
Materials and Methods 
Eligibility Criteria 
 
A search of randomised controlled trials (RCTs) was undertaken to gain the necessary data to answer 
this question. All RCTs published from 1st January 1997 to 1st January 2014 which  recruited people 
aged 65 years or over, diagnosed with dementia and presented data on their co-morbidities and/or 
detailed the medications these people were prescribed, were included. Dementia was defined as any 
form of dementia (i.e. vascular, multi-infarct, Alzheimers).  
 
Search Strategy 
 
An electronic search of the databases: AMED, CINAHL, MEDLINE, EMBASE and the Cochrane 
Clinical Trial Registry were conducted on 9th January 2014. The MEDLINE search strategy is 
presented in Supplementary Table 1. Two review authors reviewed the titles and/or full texts of all 
identified studies (TS/IM). An iterative search was adopted where initially databases from 2014 to 
2007 were searched to identify co-morbidities. The search was extended to 1997, where, no more co-
morbidities or medications were identified. It was considered that ‘saturation’ had been reached, 
therefore further searches were not required. 
 
Extraction and Appraisal 
 
Data were extracted independently by two review authors (JH/TM) using a pre-defined sheet. The 
quality of the included papers was determined using a modified version of the Critical Appraisal 
Skills Programme (CASP) RCT study tool [5]. This was undertaken by two reviewers (JH/TM). Any 
disagreements between the reviewers on data extraction or appraisal were adjudicated by a third 
reviewer (TS). 
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Data Analysis 
 
Each co-morbidity was ranked as a physical or psychological co-morbidity based on the frequency of 
the condition reported within the literature. The frequency of presentation within the included studies 
was determined, and the prevalence estimated.  
 
Results 
Search Results 
The search strategy results are presented in Supplementary Figure 1. A total of 1234 papers were 
identified from the search strategy. Following examination, nine papers were eligible and included. 
The principle reason for exclusion was the absence of data reporting on co-morbidities from study 
cohorts (94%).  
Critical Appraisal  
Supplementary Table 2 summarises the results of the critical appraisal exercise. The evidence was 
of largely moderate quality with only one study [6] assessed as low quality. Recurrent limitations 
within the evidence included not clearly documenting how co-morbidities were determined within the 
cohorts assessed (n=7), not documenting the characteristics of the cohort sufficiently clearly to 
determine generalizability to the wider population (n=8).  
Characteristics of Included Studies 
A summary of the study characteristics is presented in Supplementary Table 3. In total 1474 people 
with dementia were included; 560 males and 914 females. Mean age across the studies ranged from 
65 years [7] to 84.4 years [6]. Studies were conducted in the Ukraine [7], Japan [6], Russia [8], Brazil 
[9], Italy [10], Germany [11], Sweden [12] and the USA [13]. One study was multi-national and was 
conducted across the Netherlands, Germany, UK and USA [14].  
Dementia was diagnosed by a variety of methods. These included the  Mini Mental State Examination 
(MMSE) [8,10-14], the National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) [7,8,10,11,14], radiological investigations such as magnetic resonance imaging (MRI) and 
computed tomography [7,8,11,13,14], Diagnostic and Statistical Manual of Mental Disorders – 4th 
edition (DSM-IV) [6,8,13], Clinical Dementia Rating (CDR) [9] and the modified Haschinki 
Ischaemic Score [8]. Mean impairment scores, as assessed using the MMSE ranged from 6.9 [12] to 
24 [14].  
8 
 
Clinical Findings 
Thirteen co-morbidities were identified from the evidence-base (Table 1). The most prevalent of 
these was termed neurological disorders (prevalence 91%), vascular disorders (prevalence 91%), 
cardiac disorders (prevalence 73%) and depression (prevalence 59%). Sleep apnoea was reported in 
all 23 people in one study, but this study was specifically investigating this co-morbidity and therefore 
is  not representative of the general population of people with dementia. The least prevalent co-
morbidities were cancer (prevalence 11%), diabetes (prevalence 15%) and osteoporosis (prevalence 
27%).  
Twenty-one prescribed medications were identified. These were divided into four groups: 
cardiovascular, central nervous system, antithrombotic agents and others, and are presented in Table 
2. The others category consisted of calcium supplements, analgesics, gastric ulcer medications, 
thyroid medications and vitamin K. Overall, there was generally a low prevalence of prescribed 
medications for this population (Table 2). The most frequently prescribed medications were 
hypertensive medications, specifically prescribed with a prevalence of 74%. Following this, 
analgesics (prevalence 30%), anxiolytic drugs (prevalence 37%) and renin-angiotensin drugs were 
prescribed within the reported cohorts.  
Discussion 
This paper has provided preliminary information on common co-morbidities which are seen in people 
with dementia. Cardiovascular pathologies appear to be the most prevalent, based on both the results 
of co-morbidities reported and prescribed medications from the reported cohorts with dementia. This 
reflects the findings in elderly populations in general, irrespective of a dementia diagnosis [15]. These 
findings can be used to better inform clinicians about which conditions they can expect to see 
exhibited in this population. This is of particular relevance for dementia which can significantly 
impair a person’s capability to communicate and express their health status.  
The results are based on RCT data, and consequently these findings are likely to be based on a self-
selecting sample of the population with dementia through two means. Firstly, only people eligible to 
participate in the included trials would have been included in our analysis. Accordingly, people with 
an active infection, such as a urinary tract infection, those with unstable cardiovascular status, or those 
taking medications with contraindications for an experimental intervention would have been 
excluded. Therefore a number of important co-morbidities or medications may have been omitted 
from the review. Secondly, as the results are based on clinical trial populations, a proportion of 
participants and/or their carers may be disengaged from participating in a clinical trial due to social or 
environmental factors [16]. Accordingly, this population may have presented with different medical 
co-morbidities or prescribed medications.  
The findings acknowledge the poor reporting of co-morbidities and prescribed medications. Whilst 
nine papers presented data on the overall medical status and co-morbidities exhibited by their study 
cohorts, fifteen otherwise eligible papers did not present this data. As well as limiting the possible 
dataset available for this review, this raises a major issue about potential study generalisability of 
previous clinical trials in dementia research. Not fully appreciating the medical status and co-
morbidities of cohorts means that the reader is unable to fully generalise the findings of a specific trial 
to their own patient group. Furthermore, interventions such as medication or physical activity may be 
more or less effective for some specific participant groups dependent on their co-morbidities. 
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Therefore a major recommendation is that medical co-morbidities should be more widely reported 
within the description of cohort characteristics.  
There was variable terminology in co-morbidities. For example, vascular, cardiac and neurological 
disorders were terms used in Ihl et al’s [7] paper; these terms provide an indication of the general 
medical co-morbidity, but do not specifically describe exactly which medical conditions are 
associated with this pathology. Similarly medication usage was poorly reported with a lack of 
standardisation making it difficult to compare usage between the different studies. Some of the 
terminology used was imprecise with the potential for confusion. For example Doody et al [8] 
included the classification “psychoactive drugs” which, although not defined, appeared to include 
antidepressants, sedatives, hypnotic and antipsychotics. The same study included the classification 
anxiolytic however the difference between an anxiolytic and a psychoactive drug was not clearly 
stated. Both co-morbidities and medication usage should therefore be reported in a standardised 
fashion, for example using the WHO Anatomical Therapeutic Chemical (ATC) classification system 
(http://www.whocc.no/atc_ddd_index/) for medications.  
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Table 1. Results of identified comorbidities and prevalence values from included studies. 
Co-morbidity Number of Studies Total Number of People 
with/cohort size 
Prevalence  
(%) 
Ischaemic cerebrovascular 
disease 
2 49/92 53 
Hypertension 2 121/255 47 
Cardiovascular 2 79/193 41 
Diabetes Mellitus 2 29/193 15 
Depression 2 113/193 59 
Vascular Disorder 1 368/404 91 
Hypercholesteremia 1 79/225 35 
Osteoporosis 1 61/225 27 
Neurological Disorder 1 368/404 91 
Cardiac disorder 1 298/404 74 
Cancer 1 7/62 11 
Psychosis 1 41/132 31 
Sleep apnoea 1 23/23 100 
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Table 2. Prescribed medications people with dementia were documented as receiving in included 
studies. 
Cardiovascular Medicines 
Medication Number of Studies Total Number of 
People with/cohort size 
Prevalence  
(%) 
Renin-Angiotensin 
Drugs 
3 165/464 36 
Ca-Antagonists 2 23/434 5 
Beta-blockers 1 42/404 10 
Termed “hypertensive 
medications” 
1 73/98 74 
Vasodilators 1 3/30 10 
 
 
Central Nervous System Medicines 
Medication Number of Studies Total Number of 
People with/cohort size 
Prevalence 
(%) 
Antidepressants 2 42/94 45 
Anxiolytic drugs 1 36/98 37 
Psychoactive 
medications 
1 23/98 23 
Antipsychotics 1 3/30 10 
Sedatives 1 3/30 10 
 
 
Antithrombotic agents 
Medication Number of Studies Total Number of 
People with/cohort size 
Prevalence 
(%) 
Antithrombotic agents 2 34/434 8 
Antiplatelet drugs 1 22/98 22 
 
Others 
Medication Number of Studies Total Number of 
People with/cohort size 
Prevalence 
(%) 
Calcium supplements 1 3/30 10 
Analgesics 1 9/30 30 
Peptic Ulcer Drugs 1 6/30 20 
Vitamin K 1 3/30 10 
Thyroid therapy 1 3/30 10 
Benign prostatic 
hypertrophy drugs 
1 3/30 10 
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Supplementary Figure 1: PRISMA flow-chart presenting search results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching 
(n=3289) 
Additional records identified 
through other sources 
(n=0) 
Records after duplicates removed (n=1234) 
Records screened (n=1234) Records excluded 
(n=1209) 
 
Full-text articles assessed for eligibility  
(n = 25) 
Full-text articles excluded, 
with reasons 
(n = 16) 
No data presented on co-
morbidities (n=15) 
Unclear if dementia 
population (n=1) 
Studies included in qualitative synthesis  
(n = 9) 
Studies included in quantitative synthesis (meta-
analysis) 
(n = 0) 
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Supplementary Table 1: MEDLINE Search Strategy 
 
 
 
 
 
 
 
 
 
1. dementia.ti,ab 
2. dement*.ti,ab 
3. alzheimer*.ti,ab 
4. ((lewy* adj2 bod*)).ti,ab 
5. 1 OR 2 OR 3 OR 4  
6. (randomized AND controlled AND trial).ti,ab 
7. (controlled AND clinical AND trial).ti,abrandomi?ed.ti,ab 
8. randomly.ti,ab 
9. ((RCT OR CCT)).ti,ab 
10. 6 OR 7 OR 8 OR 9 OR 10 
11. 5 AND 11 
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Supplementary Table 2: Summary of the CASP critical appraisal results 
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3
] 
Was the cohort recruited in an acceptable 
way? 
   N/C     
Was the co-morbidity accurately 
measured to minimize bias? 
X X X   X X X X 
Was the diagnosis of dementia clearly 
presented? [1] 
        
Was the cohort typical (generalizable) of 
the dementia population? 
X X  X X N/C X  
Do the results of this study fit with other 
available evidence? 
   X     
Overall Methodological Quality 3 4 4 2 5 3 3 4 4 
 
 - yes; x – no; N/C – Not Clear;   Methodological Quality: 5/5 = high; 4-3/5 = moderate; 2-0/5 = low 
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Supplementary Table 3. Characteristics of included studies. 
 
Study Sample Size Gender (m/f) Age in years 
(mean,range,both) 
Diagnosis of Dementia Impairment score (e.g. MMSE/ 
ADAS-Cog) 
Institutional Living 
(Frequency in cohort) 
del Ser [11] n=30 
 
Treatment group: 
n=20 
 
Placebo group: 
n=10 
F = 20/30 (67%) 
M = 10/30 (33%) 
 
Treatment group: 
F = 13/20 (65%) 
M= 7/20 (45%) 
 
Control group: 
F = 7/10 (70%) 
M = 3/10 (30%) 
60-85yr 
 
Treatment group: 
73.1yr (7.4) 
 
Placebo group: 
72.6yr (5.4) 
1. Dx Probable AD with 
NINCDS-ADRDA 
2. MMSE = 16-26 
3. MRI/CT scan consistent w 
dx 
Treatment group: 
MMSE = 21.2 (3.5) 
ADAS-cog+ = 36.5 (14.3) 
Word fluency test=9.6 (3.9) 
 
Placebo group: 
MMSE = 21.7 (3.3) 
ADAS-cog+ = 35.3 (13.3) 
Word fluency test=9.8 (5.3) 
 
N/A 
 
Inclusion criteria: 
Patients needed to reside at 
home with carer 
Doody [8] Treatment group: 
n = 89 
 
Placebo group: 
n = 94 
Treatment Group:  
25:64 (M:F) 
 
Placebo Group: 
36:58 (M:F) 
Treatment Group:  
68.1yr (9.3) 
 
Placebo Group:  
68.4yr (8.7) 
DSM – IV. 
Probable AD according to 
NINCDS-ADRDA 
MMSE = 20-24. 
Modified Haschinki Ischaemic 
Score = 4 or less. 
MRI/CT scan compatible with 
diagnosis in the last 12 months. 
Treatment Group 
MMSE= 18.7 (3.3 ) 
Modified Haschinki Ischaemic 
Score = 1.6 (0.9) 
 
At Baseline;  
Placebo Group: 
MMSE= 18.3 (3.5) 
Modified Hachinki Ischaemic  
Score = 1.7 ( 1.0) 
 
None 
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Ihl  [7] 
 
n=404 
 
Treatment group: 
n=202 
 
Placebo group: 
n=202 
F=272/404 (67%) 
M=132/404 (33%) 
(p=0.524) 
 
Treatment group: 
F=139/202 (69%) 
M=63/202 (31%) 
 
Placebo group: 
F=133/202 (66%) 
M=69/202 (34%) 
 
 
Treatment group: 
65yr (10) 
 
Placebo group: 
65yr (9) 
1. Dx Probable AD with 
NINCDS-ARDA 
or 
Probable VaD with NINCDS-
ARDA 
or Probable AD w/CVD with 
NINCDS-ARDA 
2. CT/MRI consistent w dx 
3. TE4D error score ≤35 
4.SKT test = 9-23 
Treatment group: 
TE4D = 26.2(5.3) 
SKT =16.7 (3.9) 
 
Placebo group: 
TE4D = 26.0 (5.0) 
SKT = 17.2 (3.7) 
N/A 
 
Inclusion criteria: 
Outpatient status with carer 
Iwasaki [6] n=33 
 
F = 26/33  (78.8%) 
M = 7/33  (21.2%) 
(p>0.5) 
Mean=84.4yr (7.8) 
 
Treatment group: 
85.6yr (6.4) 
 
Placebo group: 
83.5yr (9.3) 
1. Dx of Dementia according to 
DSM-III 
At enrolment: 
MMSE 0-25 
Treatment group: 
MMSE = 13.5 (8.5) 
 
Placebo group: 
MMSE = 16.8 (6.3) 
All Institutional Living 
(Long Term Care Facility) 
Moraes [9] Treatment Group: 
n = 11 
 
Placebo Group:  
n = 12 
Treatment Group: 
3:8 (M:F) 
 
Placebo Group: 
5:7 (M:F) 
Treatment Group:  
76.8yr (6.2) 
 
Placebo Group:  
72.6yr (11) 
Probability criteria of the 
Alzheimer’s disease and 
related disorders association. 
Brazilian version of CDR = 1 
and 2. 
Baseline  
Treatment Group;  
MMSE = 19 (3.6) 
ADAS-cog = 34.5 (15.8) 
Placebo group: 
MMSE =17.2 (7.8) 
ADAS-cog = 29.3 (17.3) 
None 
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Scarpini [10] Open label phase  
n=254 
 
Double-blind 
phase 
Treatment group: 
n=76 
 
Placebo group: 
n=63 
Open label Phase:  
F=156/254 
(61.4%) 
M=98/254(38.6%) 
 
Treatment group:  
F=49/76 (64.5%) 
M=27/76 (35.5%) 
 
Placebo group: 
F=34/63 (54.0%) 
M=29/63 (46.0%) 
Open Label Phase  
mean = 74.2y 
 
Double Blind Phase 
Treatment group: 74.5y 
Placebo group: 74.4y 
1. Dx Probable AD with 
NINCDS-ADRDA 
2. MMSE 11-24 
Open-Label Phase: 
 
MMSE, mean: 18.9 (3.6) 
ADAS-cog/11, mean:  
24.7 (9.3) 
N/A 
 
Inclusion criteria: 
Patients needed to have 
carer 
Scheltens [14] n=212 
 
Treatment group: 
n=106 
 
Placebo group: 
n=106 
F:106/212 (50%) 
M: 106/212 (50%) 
 
Treatment:  
F=52(49%) 
M=54(51%) 
 
Control: 
F=54 (51%) 
M=52(49%) 
52-92yo mean=73.7yo 1. Dx Probable AD with 
NINCDS 
2. MMSE=20-26 
3. MRI/CT scan compatible w 
AD 
Treatment group: 
MMSE=23.8 (2.7) 
ADAS-cog=25.9(7.6) 
WMS-r delayed=1.0[01-16] 
WMS-r imm.=4.9[0-15] 
 
Placebo group: 
MMSE=24.0(2.5) 
ADAS-cog= 25.5(8.8) 
WMS-r delayed = 2.0[0-17] 
WMS-r imm. = 5.0 [0-19] 
N/A 
 
Inclusion criteria: Outpt 
status with carer 
Stenvall [12] n=64 
 
Treatment group: 
n=28 
 
Control group: 
n=36 
F:47/64 (73%) 
M: 17/64 (37%) 
 
Treatment:  
F=22(79%) 
M=6(21%) 
 
Control: 
F=25 (69%) 
M=11(31%) 
Treatment group: 81.0y 
Placebo group: 83.2y 
1. Dx Probable AD with 
NINCDS 
2. MMSE 
 
Treatment group: 
MMSE=8.6 (7.1) 
 
Placebo group: 
MMSE=6.9(5.0) 
 
Treatment group: 
Institutional Living=22 
(79%) 
 
Control group: 
Institutional Living=26 
(72%) 
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Trzepacz [13] n = 132 
 
Treatment group: 
n=63 
 
Placebo group: 
n=69 
F = 67/132 
(50.8%) 
M =65/132 
(49.2%) 
 
Treatment group: 
F = 31/63 (49.2%) 
M = 32/63 (50.8%) 
 
Placebo group: 
F = 36/69 (52.2%) 
M = 33/69 (47.8%) 
59-93yr 
77.4yr (7.87) 
 
Treatment group: 
59-93yr 
77.2yo (8.2) 
 
Placebo group: 
60-93yr 
77.7yr (7.6) 
1. Probable AD with NINCDS-
ADRDA or DSM IV-TR 
2. MMSE = 6-26 
3. NPI-10 = ≥ 10 
4. NPI-4-A/A = ≥4 
5. CT/MRI consistent with dx 
Treatment group: 
MMSE = 16.0 (6.1) 
ADAS-cog14 = 43.3 (20.4) 
NPI-10 = 31.9 (16.7) 
NPI-4-A/A = 18.8 (8.7) 
 
Placebo group: 
MMSE = 18.0 (5.3) 
ADAS-cog14 = 40.0 (18.1) 
NPI-10 = 29.7 (13.2) 
NPI-4-A/A = 18.1 (8.2) 
N/A 
 
Inclusion criteria: Pt needs 
to be community dwelling 
with carer 
 
AD, Alzheimer’s Disease; NINCDS-ARDRDA, National Institute of Neurological and Communicative Disorders and the Alzheimer’s Disease and Related Disorders 
Association; MMSE, Mini-Mental Status Examination;  MRI, magnetic resonance imaging; CT, computed tomography; ADAS-cog, Alzheimer’s Disease Assessment Scale-
cognitive subscale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; VaD, vascular dementia; TE4D, Test for Early Detection of Dementia with 
Discrimination from Depression; SKT, Short Cognitive Perfromance Test; DSM-III, Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition; CDR, clinical 
dementia rating; ADAS-cog 11, Alzheimer’s Disease Assessment Scale –Cognitive 11 Item Scale; Wechsler Memory Scale – revised; NPI-10, Neuropsychiatry Inventory; 
NPI-4-A/A, Neuropsychiatry Inventory – Agitation and Aggression; ADAS-cog 14, Alzheimer’s Disease Assessment Scale – Cognitive 14 Item Scale;  
 
 
 
 
 
 
 
 
 
